EAACI Congress 2025

Back
13 - 16 June 2025 Glasgow, United Kingdom

Initial Results from SPOTLIGHT, a Phase 1b/2a Dose Escalation Study of the anti-c-Kit Briquilimab Antibody in Adults with Chronic Inducible Urticaria (CIndU) Who Remain Symptomatic Despite H1-Antihistamine Treatment

Saturday 14 Jun, 15:00 PM - 15:12 PM Glasgow, United Kingdom